akathasia and antipsychotics in autism

Among antipsychotics, the adverse effect most commonly perceived as "increased physical activity" is akathisia, a syndrome of inner restlessness accompanied by pacing, inability to sit still, constant leg movements, rocking, or repetitive walking. It can easily be mistaken for hyperactivity, worsening ADHD, agitation, or behavioral deterioration.

The antipsychotics with the highest propensity to cause akathisia are:

High risk	Moderate risk	Low risk
Haloperidol	Risperidone	Clozapine
Fluphenazine	Lurasidone	Quetiapine
Trifluoperazine	Ziprasidone	Olanzapine
Aripiprazole*	Paliperidone	Chlorpromazine
Brexpiprazole* (less than aripiprazole)	Cariprazine*

*Partial dopamine agonists (aripiprazole, brexpiprazole, cariprazine) are particularly associated with subjective restlessness despite being second-generation antipsychotics.

In children with autism or developmental disorders, akathisia may present as:

• Increased pacing or wandering
• Constant running around
• Inability to remain seated during therapy
• Repetitive getting up and down
• Increased irritability or aggression
• Apparent "hyperactivity" after starting or increasing medication
• Sleep disturbance

This can be confused with worsening autism symptoms or ADHD unless specifically looked for.

Differential diagnosis includes:

• Akathisia (inner urge to move; movement relieves discomfort)
• Behavioral activation
• Mania (rarely medication-induced)
• Anxiety
• ADHD
• Autism-related stereotypies

Management typically involves:

1. Reducing the antipsychotic dose if feasible.
2. Switching to a lower-akathisia agent (e.g., quetiapine or olanzapine if clinically appropriate).
3. Adjunctive treatment when continuation is necessary, such as propranolol (often first-line), benzodiazepines, or anticholinergics in selected cases. Mirtazapine at low doses has also shown benefit in some studies.

For children with autism, the antipsychotics most likely to produce paradoxical increases in motor activity are:

1. Aripiprazole
2. Haloperidol
3. Risperidone (less commonly than aripiprazole but well recognized)
4. Cariprazine (limited pediatric experience)

For pediatric autism practice, the practical comparison is as follows:

Clinical pearls

Risperidone

Best studied and most widely used in children with autism.

Excellent for aggression, severe tantrums, self-injury, and irritability.

Less likely than aripiprazole to cause marked motor restlessness.

Monitor weight, prolactin, and metabolic parameters.

Aripiprazole

More activating than risperidone.

Best when sedation should be avoided.

The antipsychotic most likely to cause akathisia, presenting as:

pacing

inability to sit

constant walking

increased running around

irritability despite improvement in aggression

Starting at a low dose and titrating slowly reduces this risk.

Olanzapine

Very effective for severe aggression and agitation.

Lowest risk of akathisia among the commonly used agents.

Major limitation is substantial weight gain and metabolic syndrome.

Usually reserved for refractory cases.

Quetiapine

Useful when insomnia or anxiety is prominent.

Minimal risk of akathisia.

Evidence for treating core autism-associated irritability is weaker than for risperidone or aripiprazole.

Often limited by sedation.

Relative risk of akathisia

Drug Approximate risk

Aripiprazole High (10–25%)

Risperidone Low–Moderate (5–10%)

Olanzapine Low (<5%)

Quetiapine Very Low (<3%)

Practical approach in autism

If the child is already hyperactive or has ADHD, risperidone is often preferred over aripiprazole because aripiprazole may exacerbate motor restlessness.

If the child becomes more restless after starting an antipsychotic, consider akathisia before concluding that the autism or ADHD has worsened.

A careful history of an internal urge to move, inability to remain seated, pacing, and improvement with movement helps distinguish akathisia from baseline hyperactivity.

Slow titration, dose reduction, or switching to a lower-akathisia antipsychotic are the principal management strategies. Adjunctive propranolol is the most evidence-supported treatment when akathisia persists and there are no contraindications.